We help you ensure the ongoing provision of treatment for clinical trial participants once the trial ends, and until a medication becomes commercially available.
Following the completion of a clinical trial, pharmaceutical companies usually have a responsibility to maintain the supply of an investigational medicines to patients until it becomes available in the commercial market.
Moreover, in cases where a drug doesn’t succeed in its clinical trial or the pharmaceutical company decides to halt its development, there might still be commitments to supply the trial medication to patients who have experienced clinical benefits.
This often leads to the pharmaceutical companies to keep the clinical trial sites open which carries an ongoing expense and allocation of internal resources.
Inceptua provides pharmaceutical companies with a cost effective option to bridge the treatment gap for trial patients until the medication is commercially available, or until the patients have completed their treatment.